Back

Marea Therapeutics to present Phase 2b MAR001 data at AHA 2026

Verifying
  • Marea Therapeutics will present Phase 2b data for lead drug candidate MAR001.
  • MAR001 is an experimental antibody targeting ANGPTL4 to lower triglycerides.
  • The presentation is scheduled for the American Heart Association Scientific Sessions 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.